Oncotelic Therapeutics, Inc. Logo

Oncotelic Therapeutics, Inc.

OTLC

(0.8)
Stock Price

0,03 USD

-5.42% ROA

-41.44% ROE

-8.43x PER

Market Cap.

10.563.020,00 USD

106.94% DER

0% Yield

0% NPM

Oncotelic Therapeutics, Inc. Stock Analysis

Oncotelic Therapeutics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Oncotelic Therapeutics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (1.18x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

2 DER

The stock maintains a fair debt to equity ratio (99%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

Negative ROE (-76.06%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-61.93%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Oncotelic Therapeutics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Oncotelic Therapeutics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Oncotelic Therapeutics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Oncotelic Therapeutics, Inc. Revenue
Year Revenue Growth
1992 100.000
1993 100.000 0%
1994 300.000 66.67%
1995 100.000 -200%
1996 100.000 0%
1997 100.000 0%
1998 100.000 0%
1999 1.271.918 92.14%
2000 1.694.944 24.96%
2001 9.860.012 82.81%
2002 334.518 -2847.53%
2003 30.000 -1015.06%
2004 7.000 -328.57%
2005 1.000 -600%
2006 0 0%
2007 12.000 100%
2008 12.000 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 156.000 100%
2013 95.000 -64.21%
2014 95.000 0%
2015 0 0%
2016 0 0%
2017 -100 100%
2018 -100 0%
2019 0 0%
2020 1.740.855 100%
2021 0 0%
2022 0 0%
2023 280.000 100%
2023 70.000 -300%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Oncotelic Therapeutics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 4.800.000 100%
1997 7.300.000 34.25%
1998 10.400.000 29.81%
1999 8.397.799 -23.84%
2000 8.057.671 -4.22%
2001 6.132.283 -31.4%
2002 5.103.272 -20.16%
2003 3.938.000 -29.59%
2004 5.849.000 32.67%
2005 7.098.000 17.6%
2006 10.816.000 34.38%
2007 14.130.000 23.45%
2008 18.434.000 23.35%
2009 22.256.000 17.17%
2010 12.114.000 -83.72%
2011 5.291.000 -128.95%
2012 3.523.000 -50.18%
2013 3.636.000 3.11%
2014 7.408.000 50.92%
2015 9.086.000 18.47%
2016 8.764.000 -3.67%
2017 10.471.000 16.3%
2018 815.000 -1184.79%
2019 1.372.151 40.6%
2020 4.302.447 68.11%
2021 3.658.617 -17.6%
2022 756.910 -383.36%
2023 84.884 -791.7%
2023 61.143 -38.83%
2024 1.008 -5965.77%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Oncotelic Therapeutics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 7.438.215.000 100%
2003 5.282.000 -140721.94%
2004 4.540.000 -16.34%
2005 5.951.000 23.71%
2006 7.100.000 16.18%
2007 8.155.000 12.94%
2008 7.518.000 -8.47%
2009 8.900.000 15.53%
2010 5.885.000 -51.23%
2011 5.375.000 -9.49%
2012 4.690.000 -14.61%
2013 4.739.000 1.03%
2014 5.242.000 9.6%
2015 4.596.000 -14.06%
2016 4.995.000 7.99%
2017 3.371.000 -48.18%
2018 2.187.000 -54.14%
2019 2.938.726 25.58%
2020 5.023.142 41.5%
2021 5.467.266 8.12%
2022 4.853.664 -12.64%
2023 137.204 -3437.55%
2023 573.726 76.09%
2024 385.320 -48.9%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Oncotelic Therapeutics, Inc. EBITDA
Year EBITDA Growth
1992 -1.500.000
1993 -2.000.000 25%
1994 -2.800.000 28.57%
1995 -4.400.000 36.36%
1996 -7.200.000 38.89%
1997 -12.400.000 41.94%
1998 -15.300.000 18.95%
1999 -11.717.988 -30.57%
2000 -11.138.193 -5.21%
2001 -2.675.211 -316.35%
2002 -13.405.298 80.04%
2003 -9.668.000 -38.66%
2004 -10.811.000 10.57%
2005 -14.045.000 23.03%
2006 -20.189.000 30.43%
2007 -21.989.000 8.19%
2008 -29.110.000 24.46%
2009 -31.203.000 6.71%
2010 -12.228.000 -155.18%
2011 -11.679.000 -4.7%
2012 -8.035.000 -45.35%
2013 -8.283.000 2.99%
2014 -12.653.000 34.54%
2015 -13.690.000 7.57%
2016 -13.739.000 0.36%
2017 -13.833.000 0.68%
2018 -3.250.000 -325.63%
2019 -4.250.097 23.53%
2020 -7.220.522 41.14%
2021 -9.064.370 20.34%
2022 -5.064.248 -78.99%
2023 57.912 8844.73%
2023 -564.870 110.25%
2024 -386.320 -46.22%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Oncotelic Therapeutics, Inc. Gross Profit
Year Gross Profit Growth
1992 100.000
1993 100.000 0%
1994 300.000 66.67%
1995 100.000 -200%
1996 100.000 0%
1997 100.000 0%
1998 200.000 50%
1999 16.274 -1128.95%
2000 79.967 79.65%
2001 8.351.640 99.04%
2002 334.518 -2396.62%
2003 30.000 -1015.06%
2004 -10.473.000 100.29%
2005 -13.047.000 19.73%
2006 -17.916.000 27.18%
2007 -22.261.000 19.52%
2008 -25.928.000 14.14%
2009 0 0%
2010 0 0%
2011 0 0%
2012 156.000 100%
2013 95.000 -64.21%
2014 95.000 0%
2015 -20.000 575%
2016 -19.000 -5.26%
2017 -9.100 -108.79%
2018 -34.289 73.46%
2019 -60.603 43.42%
2020 1.740.855 103.48%
2021 -61.513 2930.06%
2022 -12.841 -379.04%
2023 280.000 104.59%
2023 70.000 -300%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Oncotelic Therapeutics, Inc. Net Profit
Year Net Profit Growth
1992 -1.600.000
1993 -2.000.000 20%
1994 -2.800.000 28.57%
1995 -3.700.000 24.32%
1996 -6.000.000 38.33%
1997 -8.100.000 25.93%
1998 -11.500.000 29.57%
1999 -10.448.865 -10.06%
2000 -9.087.446 -14.98%
2001 -4.138.610 -119.58%
2002 -11.013.327 62.42%
2003 -8.368.000 -31.61%
2004 -10.024.000 16.52%
2005 -11.909.000 15.83%
2006 -15.457.000 22.95%
2007 -20.389.000 24.19%
2008 -21.401.000 4.73%
2009 -24.728.000 13.45%
2010 -23.770.000 -4.03%
2011 -9.653.000 -146.24%
2012 -8.079.000 -19.48%
2013 -8.277.000 2.39%
2014 -12.647.000 34.55%
2015 -13.654.000 7.38%
2016 -13.654.000 0%
2017 -13.812.000 1.14%
2018 -2.737.000 -404.64%
2019 -7.387.615 62.95%
2020 -11.500.923 35.77%
2021 -11.393.855 -0.94%
2022 17.819.719 163.94%
2023 461.236 -3763.47%
2023 -7.903.093 105.84%
2024 -839.348 -841.58%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Oncotelic Therapeutics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1992 -108
1993 -120 10%
1994 -134 10.45%
1995 -151 11.26%
1996 -194 21.76%
1997 -199 2.53%
1998 -271 26.94%
1999 -244 -11.07%
2000 -195 -25.13%
2001 -88 -121.59%
2002 -211 58.29%
2003 -152 -38.82%
2004 -145 -4.83%
2005 -145 0%
2006 -134 -8.21%
2007 -175 23.43%
2008 -168 -4.79%
2009 -111 -50.45%
2010 -72 -56.34%
2011 -10 -610%
2012 -5 -100%
2013 -3 -150%
2014 -1 0%
2015 -1 0%
2016 -1 0%
2017 -1 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Oncotelic Therapeutics, Inc. Free Cashflow
Year Free Cashflow Growth
1992 -1.600.000
1993 -1.400.000 -14.29%
1994 -3.100.000 54.84%
1995 -3.300.000 6.06%
1996 -5.100.000 35.29%
1997 -8.300.000 38.55%
1998 -8.600.000 3.49%
1999 -11.332.382 24.11%
2000 -453.655 -2398.02%
2001 -9.199.857 95.07%
2002 -8.515.413 -8.04%
2003 -7.786.000 -9.37%
2004 -10.441.000 25.43%
2005 -10.610.000 1.59%
2006 -13.497.000 21.39%
2007 -17.279.000 21.89%
2008 -23.511.000 26.51%
2009 -28.778.000 18.3%
2010 -20.427.000 -40.88%
2011 -11.784.000 -73.35%
2012 -8.343.000 -41.24%
2013 -7.036.000 -18.58%
2014 -12.168.000 42.18%
2015 -11.940.000 -1.91%
2016 -15.238.000 21.64%
2017 -10.932.000 -39.39%
2018 -2.844.000 -284.39%
2019 -2.280.690 -24.7%
2020 -2.812.001 18.89%
2021 -4.434.465 36.59%
2022 -1.452.562 -205.29%
2023 -1.321.047 -9.96%
2023 -248.850 -430.86%
2024 -231.416 -7.53%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Oncotelic Therapeutics, Inc. Operating Cashflow
Year Operating Cashflow Growth
1992 -1.600.000
1993 -1.400.000 -14.29%
1994 -3.100.000 54.84%
1995 -3.300.000 6.06%
1996 -5.000.000 34%
1997 -8.100.000 38.27%
1998 -8.600.000 5.81%
1999 -11.311.021 23.97%
2000 183.245 6272.62%
2001 -9.040.752 102.03%
2002 -8.500.820 -6.35%
2003 -7.751.000 -9.67%
2004 -10.391.000 25.41%
2005 -10.498.000 1.02%
2006 -13.303.000 21.09%
2007 -17.184.000 22.58%
2008 -23.398.000 26.56%
2009 -28.669.000 18.39%
2010 -20.427.000 -40.35%
2011 -11.784.000 -73.35%
2012 -8.335.000 -41.38%
2013 -7.001.000 -19.05%
2014 -12.151.000 42.38%
2015 -11.927.000 -1.88%
2016 -15.238.000 21.73%
2017 -10.932.000 -39.39%
2018 -2.844.000 -284.39%
2019 -2.280.690 -24.7%
2020 -2.812.001 18.89%
2021 -4.434.465 36.59%
2022 -1.452.562 -205.29%
2023 -1.321.047 -9.96%
2023 -248.850 -430.86%
2024 -231.416 -7.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Oncotelic Therapeutics, Inc. Capital Expenditure
Year Capital Expenditure Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 100.000 100%
1997 200.000 50%
1998 0 0%
1999 21.361 100%
2000 636.900 96.65%
2001 159.105 -300.3%
2002 14.593 -990.28%
2003 35.000 58.31%
2004 50.000 30%
2005 112.000 55.36%
2006 194.000 42.27%
2007 95.000 -104.21%
2008 113.000 15.93%
2009 109.000 -3.67%
2010 0 0%
2011 0 0%
2012 8.000 100%
2013 35.000 77.14%
2014 17.000 -105.88%
2015 13.000 -30.77%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Oncotelic Therapeutics, Inc. Equity
Year Equity Growth
1992 -2.800.000
1993 7.200.000 138.89%
1994 4.500.000 -60%
1995 10.600.000 57.55%
1996 40.500.000 73.83%
1997 40.200.000 -0.75%
1998 30.200.000 -33.11%
1999 31.102.706 2.9%
2000 21.146.350 -47.08%
2001 18.519.666 -14.18%
2002 10.020.157 -84.82%
2003 16.470.000 39.16%
2004 29.135.000 43.47%
2005 56.534.000 48.46%
2006 43.420.000 -30.2%
2007 24.857.000 -74.68%
2008 28.739.000 13.51%
2009 5.799.000 -395.59%
2010 -5.255.000 210.35%
2011 8.797.000 159.74%
2012 4.546.000 -93.51%
2013 6.043.000 24.77%
2014 29.004.000 79.16%
2015 25.350.000 -14.41%
2016 12.500.000 -102.8%
2017 -477.000 2720.55%
2018 -362.000 -31.77%
2019 16.901.675 102.14%
2020 12.480.833 -35.42%
2021 8.158.431 -52.98%
2022 19.193.412 57.49%
2023 12.085.546 -58.81%
2023 11.611.537 -4.08%
2024 11.503.623 -0.94%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Oncotelic Therapeutics, Inc. Assets
Year Assets Growth
1992 200.000
1993 7.600.000 97.37%
1994 4.800.000 -58.33%
1995 11.200.000 57.14%
1996 41.200.000 72.82%
1997 41.200.000 0%
1998 33.000.000 -24.85%
1999 42.659.727 22.64%
2000 31.229.242 -36.6%
2001 22.153.347 -40.97%
2002 13.598.321 -62.91%
2003 20.205.000 32.7%
2004 31.757.000 36.38%
2005 60.268.000 47.31%
2006 47.642.000 -26.5%
2007 30.064.000 -58.47%
2008 35.031.000 14.18%
2009 15.617.000 -124.31%
2010 5.567.000 -180.53%
2011 11.056.000 49.65%
2012 5.447.000 -102.97%
2013 7.294.000 25.32%
2014 30.423.000 76.02%
2015 27.453.000 -10.82%
2016 14.114.000 -94.51%
2017 1.172.000 -1104.27%
2018 799.000 -46.68%
2019 23.684.781 96.63%
2020 23.663.205 -0.09%
2021 23.613.351 -0.21%
2022 36.116.819 34.62%
2023 30.096.053 -20.01%
2023 30.014.952 -0.27%
2024 29.935.173 -0.27%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Oncotelic Therapeutics, Inc. Liabilities
Year Liabilities Growth
1992 200.000
1993 400.000 50%
1994 300.000 -33.33%
1995 600.000 50%
1996 700.000 14.29%
1997 1.000.000 30%
1998 2.800.000 64.29%
1999 11.557.021 75.77%
2000 10.082.892 -14.62%
2001 3.633.681 -177.48%
2002 3.578.164 -1.55%
2003 3.735.000 4.2%
2004 2.622.000 -42.45%
2005 3.734.000 29.78%
2006 4.222.000 11.56%
2007 5.207.000 18.92%
2008 6.292.000 17.24%
2009 9.818.000 35.91%
2010 10.822.000 9.28%
2011 2.259.000 -379.06%
2012 901.000 -150.72%
2013 1.251.000 27.98%
2014 1.419.000 11.84%
2015 2.103.000 32.52%
2016 1.614.000 -30.3%
2017 1.649.000 2.12%
2018 1.161.000 -42.03%
2019 6.783.106 82.88%
2020 11.182.372 39.34%
2021 15.454.920 27.65%
2022 16.923.407 8.68%
2023 18.010.507 6.04%
2023 18.403.415 2.13%
2024 18.431.550 0.15%

Oncotelic Therapeutics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-8.43x
Price To Sales Ratio
150.9x
POCF Ratio
-8.02
PFCF Ratio
-8.12
Price to Book Ratio
0.86
EV to Sales
335.3
EV Over EBITDA
-64.7
EV to Operating CashFlow
-18.03
EV to FreeCashFlow
-18.03
Earnings Yield
-0.12
FreeCashFlow Yield
-0.12
Market Cap
0,01 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.05
Graham NetNet
-0.05

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.16
ROE
-0.1
Return On Assets
-0.17
Return On Capital Employed
-0.35
Net Income per EBT
0.95
EBT Per Ebit
1.34
Ebit per Revenue
0
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
5.71
Research & Developement to Revenue
0.47
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.01
Return on Tangible Assets
-0.05
Days Sales Outstanding
98.95
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
3.69
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,03
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.03
Interest Debt per Share
0.03
Debt to Equity
1.07
Debt to Assets
0.43
Net Debt to EBITDA
-35.58
Current Ratio
0.01
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-8922486
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0.24
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
1.23

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Oncotelic Therapeutics, Inc. Dividends
Year Dividends Growth

Oncotelic Therapeutics, Inc. Profile

About Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

CEO
Dr. Vuong Trieu Ph.D.
Employee
22
Address
29397 Agoura Road
Agoura Hills, 91301

Oncotelic Therapeutics, Inc. Executives & BODs

Oncotelic Therapeutics, Inc. Executives & BODs
# Name Age
1 Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D.
Chief Medical Officer – Translation Medicine & Director
70
2 Dr. Seymour Howard Fein M.D.
Chief Regulatory Officer & Chief Medical Officer
70
3 Dr. Vuong Trieu Ph.D.
Chairman & Chief Executive Officer
70
4 Mr. Amit Shah
Chief Financial Officer
70
5 Mr. Saranjit Saund
CBO & GM of AI Division
70
6 Mr. Steven W. King
Consultant & Director
70
7 Dr. Larn Hwang
Chief Scientific Officer
70
8 Mr. Burcak Beser
Chief Technology Officer of AI Division
70

Oncotelic Therapeutics, Inc. Competitors